Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770101 | 0.79 | MEN1 (0.46) | KCNH2HRH3METAP2HTR3A | |
| SCHEMBL27844309 | 0.75 | FGFR1 (0.51) | CDK5CDK5R1KCNH2HRH3HTR3A | |
| SCHEMBL10537216 | 0.75 | AOC3 (0.50) | MAP4K4KCNH2PIK3CAHRH3HTR3A | |
| SCHEMBL1373045 | 0.75 | KMT2A (0.51) | MAP4K4KCNH2HRH3HTR3A | |
| SCHEMBL497670 | 0.74 | GSK3B (0.52) | CDK5CDK5R1MAP4K4MINK1KCNH2 | |
| SCHEMBL14061443 | 0.74 | METAP2 (0.49) | PIK3CAMETAP2RAF1BRAFKIF11 | |
| SCHEMBL27117100 | 0.74 | AKT2 (0.52) | CDK5CDK5R1FYNPTGS2PIP4K2A | |
| Hydrochloric Acid SCHEMBL30015447 | 0.73 | GSK3B (0.50) | CDK5CDK5R1MAP4K4MINK1KCNH2 | |
| SCHEMBL7677302 | 0.73 | PTGS2 (0.62) | PTGS2KIF11 | |
| SCHEMBL10300269 | 0.73 | PTGS2 (0.62) | PTGS2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| CN-1279026-C | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LAB (US) | 2006-10-11 | — | — | CN | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
| CN-1167687-C | Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors | ���Ͽع�����˾ | 2004-09-22 | — | — | CN | disclosed |
| CN-1342149-A | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LAB (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1277605-A | Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LAB (US) | 2000-12-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | CDK5 1542/4885CDK5R1 2719/4885MAP4K4 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.